7,921 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Acquired by Freestone Grove Partners LP

Freestone Grove Partners LP bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 7,921 shares of the company's stock, valued at approximately $439,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in shares of Tarsus Pharmaceuticals by 2,088.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company's stock valued at $14,477,000 after buying an additional 420,057 shares during the last quarter. Jennison Associates LLC boosted its stake in Tarsus Pharmaceuticals by 14.8% in the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock worth $138,432,000 after purchasing an additional 321,552 shares during the period. Barclays PLC grew its stake in Tarsus Pharmaceuticals by 345.9% during the third quarter. Barclays PLC now owns 98,663 shares of the company's stock valued at $3,246,000 after acquiring an additional 76,538 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Tarsus Pharmaceuticals by 0.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,146,812 shares of the company's stock worth $63,499,000 after purchasing an additional 5,565 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Tarsus Pharmaceuticals in the 4th quarter worth about $1,107,000. 90.01% of the stock is owned by institutional investors.

Insider Transactions at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $50.00, for a total transaction of $300,000.00. Following the sale, the chief executive officer now directly owns 824,106 shares of the company's stock, valued at approximately $41,205,300. This represents a 0.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Bryan Wahl sold 3,341 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $154,654.89. Following the completion of the transaction, the general counsel now owns 58,057 shares in the company, valued at approximately $2,687,458.53. This represents a 5.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,542 shares of company stock valued at $1,581,173 in the last three months. 8.25% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Barclays dropped their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. HC Wainwright reiterated a "buy" rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Oppenheimer raised their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Guggenheim upped their price objective on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Finally, The Goldman Sachs Group boosted their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Tarsus Pharmaceuticals has an average rating of "Buy" and an average target price of $66.33.

Tarsus Pharmaceuticals Trading Down 3.5 %

NASDAQ:TARS traded down $1.66 during mid-day trading on Friday, reaching $45.48. 207,725 shares of the company's stock traded hands, compared to its average volume of 692,552. The company has a 50 day moving average price of $48.26 and a 200-day moving average price of $49.02. Tarsus Pharmaceuticals, Inc. has a 12-month low of $20.08 and a 12-month high of $57.28. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of -11.94 and a beta of 0.94. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.05. The firm had revenue of $78.34 million during the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. On average, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.